Latest news with #ASM
Yahoo
2 days ago
- Business
- Yahoo
Why Avino Silver (ASM) Dipped More Than Broader Market Today
Avino Silver (ASM) closed at $3.53 in the latest trading session, marking a -3.55% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.03%. Meanwhile, the Dow experienced a drop of 0.11%, and the technology-dominated Nasdaq saw an increase of 0.13%. Prior to today's trading, shares of the company had gained 25.77% outpaced the Basic Materials sector's gain of 3.05% and the S&P 500's gain of 0.6%. Analysts and investors alike will be keeping a close eye on the performance of Avino Silver in its upcoming earnings disclosure. On that day, Avino Silver is projected to report earnings of $0.02 per share, which would represent a year-over-year decline of 33.33%. Meanwhile, our latest consensus estimate is calling for revenue of $17.5 million, up 18.32% from the prior-year quarter. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.13 per share and a revenue of $75.15 million, indicating changes of -13.33% and +13.56%, respectively, from the former year. It is also important to note the recent changes to analyst estimates for Avino Silver. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Right now, Avino Silver possesses a Zacks Rank of #1 (Strong Buy). In the context of valuation, Avino Silver is at present trading with a Forward P/E ratio of 28.15. This expresses a premium compared to the average Forward P/E of 26.7 of its industry. The Mining - Silver industry is part of the Basic Materials sector. This industry, currently bearing a Zacks Industry Rank of 23, finds itself in the top 10% echelons of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow ASM in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Avino Silver (ASM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
BSE stock price can crash 19% as Sebi okays expiry day switch
Shares of the Bombay Stock Exchange (BSE), listed on the National Stock Exchange (NSE) declined up to 6.2 per cent in intra-day deals on Wednesday to a low of ₹2,500 after the Securities Exchange Board of India (Sebi) approved to switch the derivatives expiry day of both the stock exchanges. Derivatives contracts on the NSE will now expire on Tuesdays from September onwards, moving from the current Thursday expiry. Conversely, BSE contracts will expire on Thursdays, shifting from the current Tuesday expiry. In May, the market regulator issued a circular restricting expiries to just two days a week and asked each exchange to select one. The current expiry days will remain in effect until August 31. Analysts believe BSE could cede some market share owing to the shift in expiry days. READ MORE In recent days, BSE stock has witnessed selling pressure after the NSE placed it under the Additional Surveillance Measure (ASM) Stage-1 framework. Stocks placed under ASM framework require 100 per cent of the traded value to be blocked as margins. Further, pledging of stocks under the ASM category is barred. ALSO READ | BSE, MCX, IEX: Which exchange stock is worth your portfolio? BSE stock from its life-time high of ₹3,030 on June 10, 2025, has shed as much as 17.5 per cent at today's low. At 9:40 AM, BSE share price had recouped some of the day's losses and traded around ₹2,643 amid trades of around 4.2 million shares at the counter on the BSE. Technical chart hints at likely further pain for the stock, with a downside risk of 19.4 per cent from here on. BSE Current Price: ₹2,643 Downside Risk: 19.4% Support: ₹2,500; ₹2,359; ₹2,275 Resistance: ₹2,680; ₹2,924 The BSE stock is likely to trade with a negative bias as long as the stock remains below ₹2,924 levels. At present, the stock is seen testing resistance around its 20-Day Moving Average, which stands at 2,680. CLICK HERE FOR THE CHART The medium-term chart indicates that BSE share price can slide towards the weekly trend line support, which indicates a likely downside risk of 19.4 per cent from present levels to ₹2,130 levels. Intermediate support for the stock can be anticipated around ₹2,500, ₹2,359 and ₹2,275 levels.
Medscape
4 days ago
- Health
- Medscape
Epilepsy May Signal Future Dementia Risk
Epilepsy prevalence was significantly higher among people with frontotemporal dementia (FTD) than among those with Alzheimer's disease (AD), a new study showed, with epilepsy occurring in some cases up to 10 years before an FTD diagnosis. METHODOLOGY: In a case-control study in Finland, epilepsy prevalence and antiseizure medicine ( ASM) purchases were compared between 245 patients with FTD (mean age at diagnosis, 65 years; 49% women), more than 1300 patients with AD (mean age, 72 years; 59% women), and more than 2400 individuals matched for age, sex, and location to act as the healthy control group (mean age, 65 years; 49% women). Data were collected from 2010 to 2021, and epilepsy cases were identified using codes from the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Purchases of ASMs were tracked throughout the study period, and epilepsy prevalence was evaluated at four timepoints: 10 years before the diagnosis of FTD, 5 years before diagnosis, at diagnosis, and 5 years after diagnosis. TAKEAWAY: Both epilepsy prevalence and ASM purchases were significantly greater in patients with FTD than in those in the healthy control group at all timepoints ( P < .001 for both measures). < .001 for both measures). Epilepsy prevalence was significantly higher in patients with FTD than in patients with AD 10 years before ( P = .03), 5 years before ( P = .002), and 5 years after ( P = .05) the diagnosis of FTD. = .03), 5 years before ( = .002), and 5 years after ( = .05) the diagnosis of FTD. The prevalence of ASM use was also significantly higher among patients with FTD than among patients with AD ( P = .004 at 5 years before FTD diagnosis and P < .001 at other timepoints). = .004 at 5 years before FTD diagnosis and < .001 at other timepoints). After adjusting for age at the time of FTD diagnosis, the risk for mortality was not significantly different between patients with both FTD and epilepsy and those without epilepsy. IN PRACTICE: 'It is noteworthy that epilepsy occurred in some patients with FTD already 10 years before their dementia diagnosis, and it was more common in all the examined stages of the disease than previous international studies have reported,' lead investigator Annemari Kilpeläinen, MD, Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland, said in a press release. The researchers added that 'enhancing knowledge of the comorbidity between epilepsy and FTD could lead to more precise and comprehensive diagnostics and treatment of these conditions as well as new pathophysiologic findings.' SOURCE: The study was published online on June 2 in JAMA Neurology . LIMITATIONS: This study was limited by reliance on ICD-10 codes for classification of epilepsy types and included only two major provinces in Finland. Additionally, epilepsy diagnoses recorded before 1998 may have been missed. DISCLOSURES: This study was part of the Real-World Data Project on Neurodegenerative Diseases, funded by Roche OY. Additional funding was provided by the Kuopio University Hospital, the Finnish Brain Foundation, the Uulo Arhio Foundation, the Finnish Medical Foundation, the Finnish Cultural Foundation, the Wihuri Foundation, and the Sigrid Juselius Foundation. Several investigators reported having ties with various organizations and pharmaceutical companies. Full details are provided in the original article.
Yahoo
5 days ago
- Business
- Yahoo
ASM share buyback update June 9 – 13, 2025
Almere, The NetherlandsJune 16, 2025, 5:45 p.m. CET ASM International N.V. (Euronext Amsterdam: ASM) reports that no transactions were executed under ASM's current share buyback program in the week June 9 – 13, 2025. For further details including individual transaction information please visit: About ASM International ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol: ASM). For more information, visit ASM's website at This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Contact Investor and media relations Victor BareñoT: +31 88 100 8500 E: Investor relations Valentina FantigrossiT: +31 88 100 8502E:
New Straits Times
5 days ago
- Science
- New Straits Times
Three young Malaysian scientists to attend 74th Lindau Nobel Laureate meeting in Germany
KUALA LUMPUR: Malaysia will once again be represented on the international scientific stage, with the selection of three young scientists to attend the 74th Lindau Nobel Laureate Meeting in Germany, scheduled to take place from June 29 to July 4. The Science, Technology and Innovation Ministry, in a statement today, said this year's meeting will focus on the field of chemistry and is expected to bring together around 35 Nobel laureates and over 600 young scientists from 84 countries. Malaysia will be represented by Nur Diyan Mohd Ridzuan, 30, a PhD candidate in Applied Sciences (Chemistry) at Universiti Teknologi Petronas; Dr Ana Masara Ahmad Mokhtar, 34, a senior lecturer at the Bioprocess Technology Division, School of Industrial Technology, Universiti Sains Malaysia; and Dr Mak Kit Kay, 33, a lecturer at the Department of Pharmaceutical Chemistry, International Medical University (IMU). The ministry said the Lindau Nobel Laureate Meetings, established in 1951, provide a globally recognised forum for exchange between Nobel laureates and young scientists. Science, Technology and Innovation Minister Chang Lih Kang, in the same statement, said the participation reflects the ability of local talents to compete internationally and is in line with with the ministry's commitment to nurturing future generations of scientists through long-term investment in talent development in the fields of Science, Technology, Engineering and Mathematics (STEM). "We believe that interaction with Nobel Prize winners will broaden the horizons of our young researchers and inspire more youth to pursue careers in science, technology and innovation," he said. Meanwhile, Academy of Sciences Malaysia (ASM) president Datuk Dr Tengku Mohd Azzman Shariffadeen Tengku Ibrahim said the young Malaysian scientists will have the opportunity to present their research and expertise at the meeting, opening the door to collaboration with scientists from world-class facilities. Since 2004, ASM, as the official nominating body, has identified and nominated promising scientists each year for consideration by the scientific review panel of the Lindau Nobel Laureate Meeting. To date, a total of 89 Malaysian scientists have been selected to take part in the meeting. – Bernama
